Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues

L. Bodei, G. Pepe, G. Paganelli

Nuclear Medicine Divisions, European Institute of Oncology, Milano (Italy)

---

• Gastroenterology

Abstract. – Background: Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers.
Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.
Results and Conclusions: Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.

Corresponding Author: Giovanni Paganelli, MD; e-mail: divisione.medicinanucleare@ieo.it

Free PDF Download